Health & Medicine

STAT+: Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more

28 sec read43 views0 listens

The Trump administration's most-favored nation drug pricing deals with 16 pharmaceutical companies are set to expire after three years, impacting drug prices for cash-paying customers and Medicaid; this has introduced uncertainty in Europe regarding potential price hikes and access to medicines. For content creators, the evolving landscape of international drug pricing and its impact on healthcare systems provides a critical area for ongoing coverage and analysis.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets10 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Biotech & Pharma13 hours ago28 sec read

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

A Phase 1 clinical trial at Charité—Universitätsmedizin Berlin has shown that CAR T-cell therapy significantly reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis (RA), with three achieving sustained remiss...

Ali Nemati

Biotech & Pharma18 hours ago26 sec read

STAT+: Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

AstraZeneca's heart disease trial for its experimental drug failed, showing no additional benefits for patients already on stabilizer drugs. This setback highlights challenges in a competitive market and underscores the difficulty of improving outcom...

Ali Nemati